Safety and immunogenicity of heterologous and homologous inactivated and adenoviral-vectored COVID-19 vaccine regimens in healthy adults: a prospective cohort study건강한 성인에서 이종 및 동종 불활성화 및 아데노바이러스 매개 COVID-19 백신 요법의 안전성 및 면역원성: 전향적 코호트 연구Article Published on 2022-12-312022-09-11 Journal: Human vaccines & immunotherapeutics [Category] COVID19(2023년), MERS, SARS, 변종, 진단, 치료기술, [키워드] Adults adverse event adverse events Antibody Response AstraZeneca ChAdOx1 ChAdOx1-S circulating variants combinations CoronaVac country COVID-19 COVID-19 vaccine COVID-19 vaccines dose doses Efficacy Evidence evidence of followed by group groups healthy Heterologous heterologous adenoviral vector heterologous vaccine homologous IgA response immune response immune responses immunized immunogenicity inactivated Inactivated vaccine interferon gamma Mild neutralizing activities Neutralizing activity prospective cohort study reactogenicity Receptor-binding domain referred to regimen Safety Serious Adverse Event Serious Adverse Events supply shortage vaccination Vaccine variants variants of concern Viral viral vectored. wild-type [DOI] 10.1080/21645515.2022.2029111 PMC 바로가기 [Article Type] Article
The efficacy and effectiveness of the COVID-19 vaccines in reducing infection, severity, hospitalization, and mortality: a systematic review감염, 중증도, 입원 및 사망률 감소에 대한 COVID-19 백신의 효능 및 효과: 체계적인 검토Article Published on 2022-12-312022-09-11 Journal: Human vaccines & immunotherapeutics [Category] COVID19(2023년), SARS, 변종, [키워드] accelerated approved B.1.1.7 B.1.351 B.1.351 variants COVID-19 COVID-19 pandemic COVID-19 vaccine COVID-19 vaccines database disease transmission effective Effectiveness Efficacy effort growth Hospitalization identify inclusion criteria Infection infections Mortality Pfizer Pfizer/BioNTech populations reduced reducing regimen required Seven severity systematic literature search systematic review Vaccine Vaccine development vaccine. Vaccines variants was performed [DOI] 10.1080/21645515.2022.2027160 PMC 바로가기 [Article Type] Article
Head-to-head comparisons of the neutralizing antibody against SARS-CoV-2 variants elicited by four priming-boosting regimens4가지 프라이밍-부스팅 요법으로 유발된 SARS-CoV-2 변이체에 대한 중화 항체의 일대일 비교Article Published on 2022-12-012022-09-11 Journal: Emerging Microbes & Infections [Category] COVID19(2023년), SARS, 변종, 진단, [키워드] comparison elicited neutralizing antibody regimen SARS-CoV-2 variant [DOI] 10.1080/22221751.2022.2095931 PMC 바로가기 [Article Type] Article
Evaluation of humoral immune responses induced by different SARS-CoV-2 spike trimers from wild-type and emerging variants with individual, sequential, and combinational delivered strategiesArticle Published on 2022-12-012022-11-15 Journal: Journal of medical virology [Category] COVID19(2023년), SARS, 변종, 진단, [키워드] acute respiratory syndrome Antibody Response antibody response against autologous binding circulating coronavirus coronavirus disease COVID-19 Delta effective heterogenous homologous humoral immune response immunization immunogenicity indicated induce monovalent vaccine multivalent vaccine neutralizing antibody Neutralizing antibody response omicron produced regimen SARS-CoV-2 SARS-CoV-2 spike trimer significantly spike Spike protein spike trimer strain supported trimer Vaccination strategies Vaccination strategy Vaccine Vaccines variant Variant. variants viruses wild type wild-type [DOI] 10.1002/jmv.28081 PMC 바로가기
Managing ANCA-associated vasculitis during COVID-19 pandemic: a single-center cross-sectional studyArticle Published on 2022-12-012022-11-15 Journal: Rheumatology International [Category] 바이오마커, 진단, [키워드] Active disease ANCA-associated vasculitis Care clinical manifestations Cohort conducted COVID-19 COVID-19 infection COVID-19 severity Critical cross-sectional Cyclophosphamide death demographic died Disease activity Features Follow-up General population Immunosuppressant increased risk India Infection managing moderate non-COVID-19 patient not differ ocular outcome Patient patients patients died predicted receiving regimen required risk of COVID-19 rituximab SARS-CoV-2. severity single-center Supplemental oxygen therapy the patient Treatment Univariate analysis Vasculitis [DOI] 10.1007/s00296-022-05177-2 PMC 바로가기
Efficacy of heterologous boosting against SARS-CoV-2 using a recombinant interferon-armed fusion protein vaccine (V-01): a randomized, double-blind and placebo-controlled phase III trial재조합 인터페론 무장 융합 단백질 백신(V-01)을 사용한 SARS-CoV-2에 대한 이종 부스팅의 효능: 무작위, 이중 맹검 및 위약 대조 3상 시험Clinical Trial Published on 2022-12-012022-09-11 Journal: Emerging Microbes & Infections [Category] COVID19(2023년), SARS, 변종, 임상, 진단, [키워드] adverse event antibody assigned booster clinical trial common adverse event conducted COVID-19 vaccine COVID-19 vaccines dose double-blind dramatic increase Efficacy elicit eligible fatigue Fever fusion protein groups headache healthy Heterologous heterologous boosting Humoral immunity Identifier Immunity inactivated Inactivated vaccine Inactivated Vaccines Inc injection injection site intention-to-treat principle Malaysia Mild-to-moderate Neutralizing Neutralizing antibodies occurred Older omicron Omicron variant over Pain participant Participants Placebo placebo-controlled primary endpoint Randomized Randomly receive regimen robust Safe SARS-CoV-2 SARS-COV-2 infection second dose Serious Adverse Events subunit Subunit vaccine Subunit vaccine. Surveillance symptomatic SARS-CoV-2 infection the epidemic titre Trial Trial registration V-01 Vaccine vaccine efficacy variant virus-neutralizing antibodies was measured were assessed [DOI] 10.1080/22221751.2022.2088406 PMC 바로가기 [Article Type] Clinical Trial
Characterization and immunogenicity of SARS-CoV-2 spike proteins with varied glycosylationArticle Published on 2022-11-082022-11-15 Journal: Vaccine [Category] SARS, 진단, [키워드] 293 cells 293F cell acute respiratory syndrome addition binding caused Cell changed characterization convalescent sera coronavirus Coronavirus disease-19 COVID-19 Critical discrepancy effective Efficacy elicited exhibited expression globe glycosylated glycosylation glycosylation pattern homogeneity host cells IgG immunization immunogenicity insect cell mammalian cells mice Neutralizing antibody response neutralizing antibody titre pandemic Protein Proteins provide reactivity Receptor binding regimen robust S protein S-2P SARS-CoV-2 SARS-CoV-2 spike protein spike Spike. the S protein thermal stability Vaccine Vaccine design Variation virus virus entry while [DOI] 10.1016/j.vaccine.2022.09.057 PMC 바로가기
COVID-19 vaccine-induced antibody and T-cell responses in immunosuppressed patients with inflammatory bowel disease after the third vaccine dose (VIP): a multicentre, prospective, case-control studyArticle Published on 2022-11-012022-11-15 Journal: The Lancet. Gastroenterology & Hepatology [Category] SARS, 진단, [키워드] adjusted age All participant anti-SARS-CoV-2 anti-TNF antibody Antibody binding antibody concentration Antibody concentrations approved available data boost booster case-control study combination therapy Concentration control group COVID-19 COVID-19 vaccine Diagnosis disease dose Evidence first dose geometric mean geometric mean ratio group groups had no healthy control healthy individuals heterologous vaccine homologous IBD Immunosuppressed immunosuppressed patient immunosuppressive Immunosuppressive treatment Infection Inflammatory bowel disease jak inhibitors multicentre multivariable nine no significant difference Older Older age participant Patient patients treated Pfizer Primary outcome receiving Receptor binding domain recipient recruited reduced regimen response S1 RBD SARS-COV-2 infection SARS-CoV-2 spike SARS-CoV-2 vaccination significantly significantly lower Support T-cell Response T-cell responses the healthy therapy Tofacitinib Treatment ulcerative colitis Vaccine vaccine dose vaccine doses vaccine-induced antibody response VIP were measured [DOI] 10.1016/S2468-1253(22)00274-6 PMC 바로가기
Hamsters Protected from SARS-CoV-2 Delta Variant Challenge after Two Doses of Adjuvanted SARS-CoV-2 Recombinant Spike Protein (S-2P) and One Dose of Beta S-2PArticle Published on 2022-11-012022-11-15 Journal: The Journal of Infectious Diseases [Category] SARS, 변종, 진단, [키워드] acute respiratory syndrome Beta challenge coronavirus COVID-19 COVID-19 vaccine Delta dose Effectiveness hamster hamster challenge study highest live SARS-CoV-2 Live virus lung MVC-COV1901 neutralization Neutralizing antibody titer Omicron variant pathology prefusion PROTECT pseudovirus recombinant regimen S-2P SARS-CoV-2 SARS-CoV-2 delta SARS-CoV-2 vaccine spike Spike protein subunit Subunit vaccine suggested vaccination Vaccines variant Variant of concern. variants variants of concern virus Wuhan [DOI] 10.1093/infdis/jiac153 PMC 바로가기
Safety and immunogenicity of MVC-COV1901 vaccine in older adults: Phase 2 randomized dose-comparison trialArticle Published on 2022-11-012022-11-15 Journal: International Journal of Infectious Diseases [Category] 진단, [키워드] Administered adverse event age binding antibody clinical trial Comorbidities Comorbidity COVID-19 infection demonstrated dose double-blind elicited General population High dose High-dose immune response immunization immunogenicity immunosenescence Mild mortality rates MVC-COV1901 vaccine negative correlation Neutralizing Older older adult Older adults participant Phase 2 protein subunit vaccine Randomized regimen Registered robust Safety SARS-CoV-2. stratified subject Trial Vaccine [DOI] 10.1016/j.ijid.2022.08.021 PMC 바로가기